EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Estimating progression-free survival (PFS) and overall survival superiority during clinical trials of multiple myeloma (MM) has become increasingly challenging as novel therapeutics have improved patient outcomes. Thus, it is imperative to identify earlier end point surrogates that are predictive of long-term clinical benefit. Minimal residual disease (MRD)-negativity is a common intermediate end point that has shown prognostic value for clinical benefit in MM. This meta-analysis was based on the US Food and Drug Administration guidance for considerations for a meta-analysis of MRD as a clinical end point and evaluates MRD-negativity as an early end point reasonably likely to predict long-term clinical benefit. Eligible studies were phase 2 or 3 randomized controlled clinical trials measuring MRD-negativity as an end point in patients with MM, with follow-up of ≥6 months following an a priori–defined time point of 12 ± 3 months after randomization. Eight newly diagnosed MM studies evaluating 4907 patients were included. Trial-level associations between MRD-negativity and PFS were R2WLSiv, 0.67 (95% confidence interval [CI], 0.43-0.91) and R2copula 0.84 (0.64 to >0.99) at the 12-month time point. The individual-level association between 12-month MRD-negativity and PFS resulted in a global odds ratio (OR) of 4.02 (95% CI, 2.57-5.46). For relapse/refractory MM, there were 4 studies included, and the individual-level association between 12-month MRD-negativity and PFS resulted in a global OR of 7.67 (4.24-11.10). A clinical trial demonstrating a treatment effect on MRD is reasonably likely to eventually demonstrate a treatment effect on PFS, suggesting that MRD may be an early clinical end point reasonably likely to predict clinical benefit in MM, that may be used to support accelerated approval and thereby, expedite the availability of new drugs to patients with MM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent data show that MRD negative status (as estimated by next generation molecular methods or flow cytometry) has favorable prognostic value and may be of value as a surrogate endpoint for clinical trials in myeloma.35,108,109”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [109]
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Cancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 5,689
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationDaratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Self-citationMunshi, N. C., Avet-Loiseau, H., Rawstron, A. C., Owen, R. G., Child, J. A., Thakurta, A., Sherrington, P., Samur, M. K., Georgieva, A., Anderson, K. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3160 · Cited by 532
Paiva, B., Vidriales, M.-B., Cerveró, J., Mateo, G., Pérez, J. J., Montalbán, M. A., Sureda, A., Montejano, L., Gutiérrez, N. C., de Coca, A. G., et al. (2008) · Blood · doi:10.1182/blood-2008-05-159624 · Cited by 477
Mateos, M.-V., Cavo, M., Blade, J., Dimopoulos, M. A., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32956-3 · Cited by 444
Self-citationMunshi, N. C., Avet-Loiseau, H., Anderson, K. C., Neri, P., Paiva, B., Samur, M., Dimopoulos, M., Kulakova, M., Lam, A., Hashim, M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002827 · Cited by 431
Paiva, B., Gutiérrez, N. C., Rosiñol, L., Vídriales, M.-B., Montalbán, M.-Á., Martínez-López, J., Mateos, M.-V., Cibeira, M.-T., Cordón, L., Oriol, A., et al. (2012) · Blood · doi:10.1182/blood-2011-07-370460 · Cited by 300
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Costello, C., Efebera, Y., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 277
Research works printed but not linked: 1
- Abrams Kaplan, 2022, Multiple myeloma: top 10 advances in the past 10 years, Target Ther Oncol, 11, 70
Cited by
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M.-V., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hajek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 165
“33,34), the FDA Oncologic Drugs Advisory Committee recommended the use of MRD negativity as an end point in clinical trials involving patients with MM and provided considerations regarding timing of assessment, patient populations and trial design for future studies that intend to use MRD to…”
Self-citationShi, Q., Paiva, B., Pederson, L., Dimier, N., Talpes, E., Prior, T. J., Órfão, A., Moreau, P., Sonneveld, P., Kumar, S. K., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02020 · Cited by 52
Self-citationRemission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma
Roschewski, M. J., Kurtz, D. M., Westin, J. R., Lynch, R. C., Gopal, A. K., Alig, S., Sworder, B. J., Cherng, H.-J. J., Kuffer, C., Blair, D., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01534 · Cited by 38
Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap
Landgren, O., & Devlin, S. M. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0292 · Cited by 47
Self-citation
Metadata
- Authors
- Landgren, O., Prior, T. J., Masterson, T., Heuck, C., Bueno, O. F., Dash, A. B., Einsele, H., Goldschmidt, H., Knop, S., Li, C., Mellqvist, U.-H., McFadden, I., Oprea, C., Ross, J. A., Talpes, M., Hydren, J. R., Ahlstrom, J. M., Kazandjian, D., Weinhold, N., Zhang, R., Stetler-Stevenson, M., Marti, G., & Devlin, S. M.
- Affiliations
- University of Miami (US)
- Janssen Research & Development (United States) (US)
- AbbVie (United States) (US)
- 4Takeda, Lexington, MA
- Universitätsklinikum Würzburg (DE)
- University Hospital Heidelberg (DE)
- Nuremberg Hospital (DE)
- Takeda (United States) (US)
- Södra Älvsborg Hospital (SE)
- Amgen (United States) (US)
- Sanofi (France) (FR)
- 11HealthTree Foundation, Lehi, UT
- Heidelberg University (DE)
- 12National Cancer Institute, National Institutes of Health, Bethesda, MD
- National Institutes of Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Landgren, Ola
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2024-07-25
- Volume
- 144
- Issue
- 4
- Pages
- 359-367
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC11418064
- OpenAlex
- W4398143893
- Cited by
- 131
- References
- 29
- Citations by year
- 2026: 47 · 2025: 69 · 2024: 15
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Blood (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA008748, P30CA240139)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, minimal residual disease, MRD negativity, progression-free survival, surrogate endpoints, accelerated approval, newly diagnosed multiple myeloma, relapsed/refractory multiple myeloma, treatment response prediction
- MeSH terms
- Progression-Free Survival, Humans, Multiple Myeloma, Prognosis, Randomized Controlled Trials as Topic, Neoplasm, Residual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. https://app.cochat.ai/papers/10.1182/blood.2024024371
- The paper
- Landgren, O., Prior, T. J., Masterson, T., Heuck, C., Bueno, O. F., Dash, A. B., Einsele, H., Goldschmidt, H., Knop, S., Li, C., Mellqvist, U.-H., McFadden, I., Oprea, C., Ross, J. A., Talpes, M., Hydren, J. R., Ahlstrom, J. M., Kazandjian, D., Weinhold, N., . . . Devlin, S. M. (2024). EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. https://doi.org/10.1182/blood.2024024371
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.